Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The role of orexin-1 receptor signaling in demand for the opioid fentanyl
Jennifer E. Fragale, Caroline B. Pantazis, Morgan H. James, et al.
Neuropsychopharmacology (2019) Vol. 44, Iss. 10, pp. 1690-1697
Open Access | Times Cited: 68

Showing 26-50 of 68 citing articles:

A common limiter circuit for opioid choice and relapse identified in a rodent addiction model
Jasper A. Heinsbroek, Giuseppe Giannotti, Mitchel R. Mandel, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 25
New directions in modelling dysregulated reward seeking for food and drugs
Robyn M. Brown, Christopher V. Dayas, Morgan H. James, et al.
Neuroscience & Biobehavioral Reviews (2021) Vol. 132, pp. 1037-1048
Open Access | Times Cited: 23
Oxytocin and orexin systems bidirectionally regulate the ability of opioid cues to bias reward seeking
Giuseppe Giannotti, Francesca Mottarlini, Jasper A. Heinsbroek, et al.
Translational Psychiatry (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 17
Suvorexant, an FDA-approved dual orexin receptor antagonist, reduces oxycodone self-administration and conditioned reinstatement in male and female rats
Jessica M. Illenberger, Francisco J. Flores‐Ramirez, Alessandra Matzeu, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 9
Orexin-mediated Motivated Arousal and Reward Seeking.
Theresa E. Bjorness, Robert Greene
Peptides (2024) Vol. 180, pp. 171280-171280
Closed Access | Times Cited: 3
Targeting the orexin system for prescription opioid use disorder: Orexin-1 receptor blockade prevents oxycodone taking and seeking in rats
Alessandra Matzeu, Rémi Martin‐Fardon
Neuropharmacology (2019) Vol. 164, pp. 107906-107906
Open Access | Times Cited: 28
The orexin-1 receptor antagonist SB-334867 reduces motivation, but not inhibitory control, in a rat stop signal task
Joost Wiskerke, Morgan H. James, Gary Aston‐Jones
Brain Research (2019) Vol. 1731, pp. 146222-146222
Open Access | Times Cited: 26
A novel dual agonist of glucagon-like peptide-1 receptors and neuropeptide Y2 receptors attenuates fentanyl taking and seeking in male rats
Yafang Zhang, Suditi Rahematpura, Kael Ragnini, et al.
Neuropharmacology (2021) Vol. 192, pp. 108599-108599
Open Access | Times Cited: 22
Lateral Hypothalamic Orexin Neurons Mediate the Reward Effects of Pain Relief Induced by Electroacupuncture
Can Wang, Mei‐Yu Chen, Chuan Qin, et al.
Frontiers in Molecular Neuroscience (2022) Vol. 15
Open Access | Times Cited: 15
Introduction to the Special Issue: “Making orexin-based therapies for addiction a reality: What are the steps from here?”
Morgan H. James, Gary Aston‐Jones
Brain Research (2020) Vol. 1731, pp. 146665-146665
Open Access | Times Cited: 22
Targeting the Orexin System for Prescription Opioid Use Disorder
Alessandra Matzeu, Rémi Martin‐Fardon
Brain Sciences (2020) Vol. 10, Iss. 4, pp. 226-226
Open Access | Times Cited: 22
Intermittent nicotine access is as effective as continuous access in promoting nicotine seeking and taking in rats
Hajer E. Algallal, Vincent Jacquemet, Anne‐Noël Samaha
Psychopharmacology (2024) Vol. 241, Iss. 6, pp. 1135-1149
Open Access | Times Cited: 2
Changes in fentanyl demand following naltrexone, morphine, and buprenorphine in male rats
Lindsey R. Hammerslag, Rebecca S. Hofford, Qiwen Kang, et al.
Drug and Alcohol Dependence (2019) Vol. 207, pp. 107804-107804
Open Access | Times Cited: 21
Aberrant Feeding and Growth in Neonates With Prenatal Opioid Exposure: Evidence of Neuromodulation and Behavioral Changes
Elizabeth Yen, Jill L. Maron
Frontiers in Pediatrics (2022) Vol. 9
Open Access | Times Cited: 12
Impacts of xylazine on fentanyl demand, body weight, and acute withdrawal in rats: A comparison to lofexidine
Safiyah Sadek, Shailesh Khatri, Zachary Kipp, et al.
Neuropharmacology (2023) Vol. 245, pp. 109816-109816
Open Access | Times Cited: 6
Endogenous opiates and behavior: 2019
Richard J. Bodnar
Peptides (2021) Vol. 141, pp. 170547-170547
Closed Access | Times Cited: 15
Intermittent self-administration of fentanyl induces a multifaceted addiction state associated with persistent changes in the orexin system
Jennifer E. Fragale, Morgan H. James, Gary Aston‐Jones
bioRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 15
Utility of ‘substance use disorder’ as a heuristic for understanding overeating and obesity
Richard M. O’Connor, Paul J. Kenny
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2022) Vol. 118, pp. 110580-110580
Open Access | Times Cited: 9
Daily treatment with the dual orexin receptor antagonist DORA-12 during oxycodone abstinence decreases oxycodone conditioned reinstatement
Jessica M. Illenberger, Francisco J. Flores‐Ramirez, Glenn Pascasio, et al.
Neuropharmacology (2023) Vol. 239, pp. 109685-109685
Open Access | Times Cited: 5
The dual orexin/hypocretin receptor antagonist suvorexant reduces addiction-like behaviors for the opioid fentanyl
Shayna L. O’Connor, Jennifer E. Fragale, Morgan H. James, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 12
The Long-Acting D3 Partial Agonist MC-25-41 Attenuates Motivation for Cocaine in Sprague-Dawley Rats
Gregory L. Powell, Mark D. Namba, Annika Vannan, et al.
Biomolecules (2020) Vol. 10, Iss. 7, pp. 1076-1076
Open Access | Times Cited: 12
Machine Learning Models to Predict Ligand Binding Affinity for the Orexin 1 Receptor
Vanessa Zhang, Shayna L. O’Connor, William J. Welsh, et al.
Artificial Intelligence Chemistry (2023) Vol. 2, Iss. 1, pp. 100040-100040
Open Access | Times Cited: 4
Emerging medications and pharmacological treatment approaches for substance use disorders
Joel S. Raymond, Anastasios Athanasopoulos, Connie J. Badolato, et al.
Pharmacology Biochemistry and Behavior (2024) Vol. 248, pp. 173952-173952
Open Access | Times Cited: 1
Central blockade of orexin type 1 receptors reduces naloxone induced activation of locus coeruleus neurons in morphine dependent rats
Niloofar Aghajani, Mahsa Pourhamzeh, Hossein Azizi, et al.
Neuroscience Letters (2021) Vol. 755, pp. 135909-135909
Closed Access | Times Cited: 10
Potential therapeutic targets for the treatment of opioid abuse and pain
Norikazu Kiguchi, Mei‐Chuan Ko
Advances in pharmacology (2022), pp. 335-371
Closed Access | Times Cited: 7

Scroll to top